NEWTON, Mass. (AP) — NEWTON, Mass. (AP) — Karyopharm Therapeutics Inc. (KPTI) on Wednesday reported a fourth-quarter loss of $38.5 million, after reporting a profit in the same period a year earlier.
On a per-share basis, the Newton, Massachusetts-based company said it had a loss of 43 cents.
The results did not meet Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 34 cents per share.
The pharmaceutical company posted revenue of $33.6 million in the period, which also fell short of Street forecasts. Six analysts surveyed by Zacks expected $33.9 million.
For the year, the company reported that its loss widened to $165.3 million, or $2.02 per share. Revenue was reported as $157.1 million.
Karyopharm Therapeutics expects full-year revenue in the range of $160 million to $175 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a KPTI">Zacks stock report on KPTI at https://www.zacks.com/ap/KPTI